Combining radiation therapy with interleukin-3 gene immunotherapy

Cancer Gene Therapy

Volumn 7, Issue 8, 2000, Pages 1172-1178

  Chiang, Chi Shiun ^a   Hong, Ji Hong ^a   Wu, Yuan Chou ^a   Mcbride, William H ^b   Dougherty, Graeme J ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Immunotherapy; Interleukin 3; Radiation therapy

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 3; MESSENGER RNA; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE THERAPY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALIA; MURINAE;

EID: 0033837349     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700217     Document Type: Article

References (39)

1. Sensitization of renal carcinoma to radiation using a interferon (IFNA) gene transfection
2. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
3. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells
4. Combined effects of angiostatin and ionizing radiation in antitumor therapy
5. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposure to angiostatin
6. Synergistic anti-tumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation
7. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intra-cranial tumors
8. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
9. Murine interleukin-4 displays potent anti-tumor activity in vivo
10. Murine tumor cells transduced with the gene for tumor necrosis factor-α: Evidence for a paracrine immune effect of tumor necrosis factor against tumors
11. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
12. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
13. Interleukin-3 in gene therapy of cancer
14. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host Cell infiltration and tumor immunity
15. Modification of tumor microenvironment by cytokine gene transfer
16. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism
17. Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo
18. Tumor-directed cytokine gene therapy
19. Cellular and molecular mechanisms that direct leukocyte traffic
20. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcg receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis
21. Isolation of two cDNAs encoding novel a1-antichymotrypsin-like proteins in a murine chondrocytic cell line
22. A cytotoxic activated macrophage effector molecule
23. Role of nitric oxide in pancreatic tumor growth: In vivo and in vitro studies
24. IL-3 enhances presentation of exogenous tumor antigen with class I by a rare subpopulation of host macrophages
25. + hematopoietic progenitor cells
26. Tumor-induced immune dysfunction: The macrophage connection
27. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses
28. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma Induction of regulatory macrophages in normal mice by in vivo administration of rGM-CSF
29. Cytokine production by lymphoreticular cells from mammary tumor-bearing mice: The role of tumor-derived factors
30. Histologic and functional analysis of the primary immune response to tumors transfected with IL-2, IL-3, IL-4, IL-6, IFN-r, or GM-CSF
31. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes
32. Interleukin 3 enhances cytotoxic T lymphocyte development and class major histocompatibility complex 're-presentation' of exogenous antigen by tumor-infiltrating antigen-presenting cells
33. Regulation of macrophage activation by IL-3: IL-3 functions as a macrophage-activating factor with unique properties, inducing Ia and lymphocyte function-associated antigen-1 but not cytotoxicity
34. Regulation of macrophage activation by IL-3: IL-3 and lipopolysaccharide act synergistically in the regulation of IL-1 expression
35. IL-3-mediated enhancement of particulate antigen presentation by macrophages
36. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene
37. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide
38. Paradoxical preservation of a lipopolysaccharide response in C3H/HeJ macrophages: Induction of matrix metalloproteinase-9
39. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation